Weekly · monthly · quarterly news summaries, side by side in time
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud lawsuits pile up ahead of August 10 deadline Multiple law firms filed or reminded investors of class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue. The August 10 lead-plaintiff deadline keeps legal risk and uncertainty in focus, weighing on the stock.
This is the main new development this period and directly pressures ADMA's price through legal risk.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
Securities fraud class actions pile up Multiple law firms filed class actions alleging ADMA hid a related-party deal and used channel stuffing to inflate revenue, with a lead plaintiff deadline of August 10, 2026. These lawsuits keep legal risk and uncertainty in focus, weighing on the stock.
This is the main new event of the period and directly pressures ADMA's price through legal and reputational risk.
Underlying business still growing ADMA reported 28% year-over-year revenue growth from ASCENIV last quarter and is advancing SG-001, a hyperimmune globulin candidate, while new manufacturing efficiencies expand margins. This shows the core business remains healthy despite the legal cloud.
It provides the real counterweight to the negative legal news, showing why the stock isn't only about lawsuits.
CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.
This is the biggest new development, directly driving the stock's recent jump and future growth prospects.
BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.
This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.
Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.
This is a new earnings report that directly affects investor expectations for future profits.
New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.
This is a new governance change that could improve strategic direction, though its impact is longer-term.
CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.
This is the biggest new development, directly driving the stock's recent jump and future growth prospects.
BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.
This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.
Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.
This is a new earnings report that directly affects investor expectations for future profits.
New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.
This is a new governance change that could improve strategic direction, though its impact is longer-term.
CSL Plasma to roll out NexSys across all U.S. centers by end-2027 CSL Plasma now expects to complete the rollout of Haemonetics' NexSys PCS devices and Persona PLUS disposables across all its U.S. plasma collection centers by the end of 2027. This is a major expansion of the August supply deal and could significantly boost future sales and profits, though Haemonetics has not yet updated its financial guidance.
This is the biggest new development, directly driving the stock's recent jump and future growth prospects.
BofA upgrades HAE to Buy, raises target to $123 on CSL deal Bank of America upgraded Haemonetics to Buy from Neutral and raised its price target to $123 from $92, citing the CSL supply deal. The analyst expects the deal to lift organic revenue growth, operating margins, and earnings per share over the next several years, which supports a higher stock price.
This is a new analyst action that validates the CSL deal's positive impact and can attract more investors.
Q1 earnings beat, fiscal 2027 guidance raised Haemonetics reported first-quarter revenue of $339 million, up 6% organically, and raised its full-year fiscal 2027 guidance. Adjusted EPS rose 4% to $1.14. Strong plasma and MedSurg growth, plus the Persona PLUS rollout, drove the beat and higher outlook, signaling healthy business momentum.
This is a new earnings report that directly affects investor expectations for future profits.
New board member brings operational and strategic expertise Haemonetics elected Martin Madaus to its Board of Directors. Dr. Madaus has over 30 years of leadership experience in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics and Millipore. His expertise is expected to support growth and long-term value creation, a positive but gradual influence.
This is a new governance change that could improve strategic direction, though its impact is longer-term.